Fortuna Mining Corp. Common Shares vs Heron Therapeutics Inc — how do they compare? Fortuna Mining Corp. Common Shares trades at $10.76 (market cap $3.01B), while Heron Therapeutics Inc trades at $0.37 (market cap $74.04M). The key difference: Fortuna Mining Corp. Common Shares is far larger — about 40.7× Heron Therapeutics Inc's market cap, and Fortuna Mining Corp. Common Shares is trading nearer its 52-week high, Heron Therapeutics Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Fortuna Mining Corp. Common Shares for 0 Days and Heron Therapeutics Inc for 35 Days on average.
| FSM | HRTX | |
|---|---|---|
Market Cap | $3.01B | $74.04M |
Volume | 10,925,733 | 3,668,095 |
Sector | Basic Materials | Health |
52-Week High | $13.66 | $1.49 |
52-Week Low | $7.84 | $0.27 |
Typical Hold Time | 0 Days | 35 Days |
Enterprise Value | $2.63B | $180.78M |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
HRTX trades at $0.39, up 17.58% today, with a bullish technical signal from moving averages. The company reported Q2 2026 revenue of $37.7 million but missed EPS estimates with a $0.03 loss. Despite negative profitability metrics, analyst consensus remains strongly positive with 89% buy ratings. Recent news highlights ongoing comparisons with peers and earnings performance discussions.
The outlook is mixed: strong analyst support and technical momentum suggest potential upside, but persistent losses and high valuation ratios pose significant risks. Investment opportunity hinges on revenue growth translating to profitability, while key risks include execution challenges and competitive pressures in the biotechnology sector.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Fortuna Mining is a Canadian precious-metals mining company with operations in Latin America and West Africa. It produces gold and silver and conducts exploration activities in several countries.
Read more on FSM →Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →